Paper41890397
Efficient Synthesis of Enlicitide Chloride through Convergent Solution-Phase and Hybrid Solution-Solid-Phase Strategies.
Zhao X and 5 others. Precis Chem, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Efficient Synthesis of Enlicitide Chloride through Convergent Solution-Phase and Hybrid Solution-Solid-Phase Strategies. Papers, record 41890397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41890397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficient Synthesis of Enlicitide Chloride through Convergent Solution-Phase and Hybrid Solution-Solid-Phase Strategies.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27854420 | Heart Disease and Cancer Deaths - Trends and Projections in the United States, 1969-2020. | Prev Chronic Dis | 2016 | https://conductscience.org/library/papers/27854420 | PubMed |
| 2 | 30448414 | Small molecules as inhibitors of PCSK9: Current status and future challenges. | Eur J Med Chem | 2019 | https://conductscience.org/library/papers/30448414 | PubMed |
| 3 | 25825402 | Cardiology patient page. Statin intolerance. | Circulation | 2015 | https://conductscience.org/library/papers/25825402 | PubMed |
| 4 | 33536635 | Trends in peptide drug discovery. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33536635 | PubMed |
| 5 | 34704436 | A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors. | J Med Chem | 2021 | https://conductscience.org/library/papers/34704436 | PubMed |
| 6 | 40123407 | Total Synthesis of Enlicitide Decanoate. | J Am Chem Soc | 2025 | https://conductscience.org/library/papers/40123407 | PubMed |
| 7 | 36446632 | Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. | J Med Chem | 2022 | https://conductscience.org/library/papers/36446632 | PubMed |
| 8 | 35121175 | Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia. | Drug Discov Today | 2022 | https://conductscience.org/library/papers/35121175 | PubMed |
| 9 | 37125593 | Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. | Circulation | 2023 | https://conductscience.org/library/papers/37125593 | PubMed |
| 10 | 30879355 | 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. | Circulation | 2019 | https://conductscience.org/library/papers/30879355 | PubMed |
| 11 | 28970592 | A Therapeutic Peptide Vaccine Against PCSK9. | Sci Rep | 2017 | https://conductscience.org/library/papers/28970592 | PubMed |
| 12 | 29438441 | Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice. | PLoS One | 2018 | https://conductscience.org/library/papers/29438441 | PubMed |
| 13 | 31599007 | A gold mine for drug discovery: Strategies to develop cyclic peptides into therapies. | Med Res Rev | 2020 | https://conductscience.org/library/papers/31599007 | PubMed |
| 14 | 25773378 | Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. | N Engl J Med | 2015 | https://conductscience.org/library/papers/25773378 | PubMed |
| 15 | 36889610 | Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616. | J Am Coll Cardiol | 2023 | https://conductscience.org/library/papers/36889610 | PubMed |
| 16 | 34246818 | The emerging landscape of peptide-based inhibitors of PCSK9. | Atherosclerosis | 2021 | https://conductscience.org/library/papers/34246818 | PubMed |
| 17 | 27959715 | A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. | N Engl J Med | 2017 | https://conductscience.org/library/papers/27959715 | PubMed |
| 18 | 31784033 | The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients. | Atherosclerosis | 2020 | https://conductscience.org/library/papers/31784033 | PubMed |
| 19 | 19930098 | The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis. | J Intern Med | 2009 | https://conductscience.org/library/papers/19930098 | PubMed |
| 20 | 23485362 | Gene silencing approaches for the management of dyslipidaemia. | Trends Pharmacol Sci | 2013 | https://conductscience.org/library/papers/23485362 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| LDLR | 3949 | PubTator's text mining | https://conductscience.org/library/genes/3949 | NCBI Gene |
| PCSK9 | 255738 | PubTator's text mining | https://conductscience.org/library/genes/255738 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41890397
GET https://conductscience.org/api/papers/v1/41890397/references?page=2